SCHEMBL7674553

SCHEMBL7674553

COc1ccc(C(=O)CS(=O)(=O)NCC(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.57
PDE4B Q07343 1/20 0.51
MAPT P10636 2/20 0.50
GSK3B P49841 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
CA12 O43570 1/20 0.48
CA9 Q16790 1/20 0.48
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899545 0.80 CA1 (0.55) HSD11B1PDE4BMAPTGSK3BHDAC3
SCHEMBL21115781 0.79 HSD11B1 (0.64) HSD11B1PDE4BMAPTGSK3BHDAC3
SCHEMBL4621546 0.79 MAPT (0.52) HSD11B1PDE4BMAPTGSK3BHDAC3
SCHEMBL4174812 0.77 MMP8 (0.75) MAPTCA1CA2CA12CA9
SCHEMBL5899592 0.77 MMP8 (0.52) HSD11B1MAPTGSK3BHDAC3HDAC4
SCHEMBL2427418 0.76 PDE4B (0.66) PDE4BMAPTGSK3BHDAC3HDAC4
SCHEMBL4173740 0.75 MEP1B (0.67) MAPTCA1CA2NPC1RAB9A
SCHEMBL27397149 0.73 HSD11B1 (0.60) HSD11B1PDE4BMAPTGSK3BHDAC3
SCHEMBL153386 0.73 ALDH1A1 (0.76) PDE4BMAPTGSK3BHDAC3HDAC4
SCHEMBL6203408 0.73 HSD11B1 (1.00) HSD11B1NPC1RAB9AALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US claimed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP claimed
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed